Gynakologisch-geburtshilfliche Rundschau最新文献_第6页

[Predicting response to therapy in breast cancer]. [预测乳腺癌治疗的反应]。

Gynakologisch-geburtshilfliche Rundschau Pub Date : 2008-01-01 Epub Date: 2008-06-17 DOI: 10.1159/000127392

K Strunz, H Deissler, R Kreienberg, G Sauer

{"title":"[Predicting response to therapy in breast cancer].","authors":"K Strunz, H Deissler, R Kreienberg, G Sauer","doi":"10.1159/000127392","DOIUrl":"https://doi.org/10.1159/000127392","url":null,"abstract":"Molecular staging of breast cancer with microarray technologies leads to different gene expression profiles distinguishing 4 special groups: luminal A and B subtype, HER2 subtype and basal subtype. These 4 groups show a different prognosis as well as different behaviours and responses to adjuvant therapy. The development of gene expression profiles to classify breast cancer may contribute to the targeted institution of adjuvant therapies. Especially the 21-gene recurrence score (Oncotype DX) and the 70-gene profile (Mamma-print) have become intensively examined prognostic and predictive tools. As chemotherapy is an integral component of adjuvant therapy in early breast cancer but estrogen-receptor-positive breast cancer is the most common type, patient selection for adjuvant chemotherapy is of particular interest. In instances when the benefit from chemotherapy seems modest, there is a decision making tool beside traditional histopathological parameters that might provide additional objective prognostic and predictive information. Those genomic decision making approaches may yield more rational treatment choices and may keep patients from systemic treatment modalities of lower value.","PeriodicalId":12827,"journal":{"name":"Gynakologisch-geburtshilfliche Rundschau","volume":"48 3","pages":"113-7"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000127392","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27510374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

[Fetal growth retardation and diseases in adult life]. [胎儿发育迟缓与成人疾病]。

Gynakologisch-geburtshilfliche Rundschau Pub Date : 2008-01-01 Epub Date: 2008-12-03 DOI: 10.1159/000154804

Ernst Beinder

引用次数: 4

[Imatinib--a possible therapeutic option for cervical carcinoma: results of a preclinical phase I study]. 伊马替尼——宫颈癌的一种可能的治疗选择:临床前I期研究的结果。

Gynakologisch-geburtshilfliche Rundschau Pub Date : 2008-01-01 Epub Date: 2008-04-16 DOI: 10.1159/000119032

S Kummel, H Heidecke, B Brock, C Denkert, J Hecktor, A Koninger, I Becker, J Sehouli, A Thomas, J U Blohmer, W Lichtenegger, R Kimmig

{"title":"[Imatinib--a possible therapeutic option for cervical carcinoma: results of a preclinical phase I study].","authors":"S Kummel, H Heidecke, B Brock, C Denkert, J Hecktor, A Koninger, I Becker, J Sehouli, A Thomas, J U Blohmer, W Lichtenegger, R Kimmig","doi":"10.1159/000119032","DOIUrl":"https://doi.org/10.1159/000119032","url":null,"abstract":"Background: In the last few years, the therapy of cervical carcinoma has progressed substantially due to the use of simultaneous platinum- containing radiochemotherapy. However, there are no data which evaluate an individualized treatment adapted to tumor biology, in spite of the fact that patients show remarkably different responses to chemotherapy. Therefore this preclinical phase I study aims at finding therapeutic alternatives to the current cytostatic drugs to treat cervical carcinoma.Material and methods: In a tumor chemosensitivity assay, 8 drugs were tested on freshly isolated tumor cells of 16 patients [carbo- and cisplatin, topotecan, paclitaxel as well as the 2 tyrosine kinase inhibitors imatinib (Glivec) and gefitinib (Iressa (R) ) and the 2 monoclonal antibodies cetuximab (Erbitux) and trastuzumab (Herceptin (R) )].Results: Overall the test was evaluable for 16 specimens (100%). Ten of 15 tumor samples (66.6%) were sensitive to imatinib. A sensitive therapeutic response could be demonstrated in all tested FIGO stages. An interindividual comparison could establish sensitivity to cetuximab in 12.5% of cases, to gefitinib in 6.25%, to trastuzumab in 6.6%, to cisplatin in 13.3%, to carboplatin in 7.6%, to paclitaxel in 93.8% and to topotecan in 25%.Conclusion: Imatinib seems to be an efficacious therapeutic option for patients with cervical carcinoma, independently of tumor subtype.","PeriodicalId":12827,"journal":{"name":"Gynakologisch-geburtshilfliche Rundschau","volume":"48 2","pages":"94-100"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000119032","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27398539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

[Fundamental advances in the adjuvant systemic therapy of breast cancer]. 【乳腺癌辅助全身治疗的基本进展】

Gynakologisch-geburtshilfliche Rundschau Pub Date : 2008-01-01 Epub Date: 2008-06-17 DOI: 10.1159/000127391

D Fink, U Lang, R Kimmig

引用次数: 1

Breast-conserving treatment of breast cancer--oncological and reconstructive aspects. 乳腺癌保乳治疗——肿瘤学和重建方面。

Gynakologisch-geburtshilfliche Rundschau Pub Date : 2008-01-01 Epub Date: 2008-04-16 DOI: 10.1159/000118932

Stefan Kramer, Maren Darsow, Sherko Kummel, Rainer Kimmig, Mahdi Rezai

引用次数: 27

Autologous and alloplastic breast reconstruction--overview of techniques, indications and results. 自体和同种异体乳房重建-技术，适应症和结果概述。

Gynakologisch-geburtshilfliche Rundschau Pub Date : 2008-01-01 Epub Date: 2008-04-16 DOI: 10.1159/000118934

Mahdi Rezai, Maren Darsow, Sherko Kummel, Stefan Kramer

{"title":"Autologous and alloplastic breast reconstruction--overview of techniques, indications and results.","authors":"Mahdi Rezai, Maren Darsow, Sherko Kummel, Stefan Kramer","doi":"10.1159/000118934","DOIUrl":"https://doi.org/10.1159/000118934","url":null,"abstract":"It is important for any woman undergoing mastectomy to make an informed decision about reconstruction and to be provided with information about the technique, advantages and disadvantages. There is a high degree of patient satisfaction with breast reconstruction, but high levels of preoperative information and psychological support are necessary. Close collaboration between oncological and reconstructive surgeons or management by an oncoplastic breast surgeon, careful patient selection and counseling, and refinements in surgical techniques can provide a range of safe and predictable techniques for breast reconstruction. After modified radical mastectomy breast reconstruction involves replacement of breast skin and breast volume; after skin-sparing mastectomy only the replacement of breast volume is necessary. The most commonly used surgical techniques are tissue expansion, latissimus dorsi myocutaneous flap with or without implants, and the use of lower abdominal tissue. Until today, the pedicled TRAM flap is the standard method for autologous breast reconstruction.","PeriodicalId":12827,"journal":{"name":"Gynakologisch-geburtshilfliche Rundschau","volume":"48 2","pages":"68-75"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000118934","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27398536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 18

[Quality control and quality of life after uterine fibroid embolization: long-term results]. 子宫肌瘤栓塞后的质量控制与生活质量:远期结果。

Gynakologisch-geburtshilfliche Rundschau Pub Date : 2008-01-01 Epub Date: 2008-04-16 DOI: 10.1159/000118936

F Hirzel, T Hess, C Zollikofer

引用次数: 3

[Urethral diverticulum as a cause for chronic genitourinary pain: a case report]. 【尿道憩室引起慢性泌尿生殖系统疼痛1例】。

Gynakologisch-geburtshilfliche Rundschau Pub Date : 2008-01-01 Epub Date: 2008-01-17 DOI: 10.1159/000111469

Barbara Blochlinger-Wegmann, Matthias Werner, David Scheiner, Daniel Fink, Daniele Perucchini

引用次数: 0

[Collagen matrix mesh implants (Veritas) in the surgical therapy of cystocele]. 胶原基质网状植入物(Veritas)在膀胱膨出手术治疗中的应用。

Gynakologisch-geburtshilfliche Rundschau Pub Date : 2008-01-01 Epub Date: 2008-01-17 DOI: 10.1159/000111468

Christian Gopel, Sandra Storer, Eva Kantelhardt

{"title":"[Collagen matrix mesh implants (Veritas) in the surgical therapy of cystocele].","authors":"Christian Gopel, Sandra Storer, Eva Kantelhardt","doi":"10.1159/000111468","DOIUrl":"https://doi.org/10.1159/000111468","url":null,"abstract":"Collagen Matrix Mesh Implants (Veritas) in the Surgical Therapy of Cystocele Introduction: Grade 3 and 4 cystocele repair using Veritas TM collagen matrix implants was carried out in a preliminary study to assess the feasibility and efficacy of the Veritas collagen matrix implant for the treatment of recurrent cystocele. Material and Methods: Eighteen patients who underwent anterior vaginal wall repair via a vaginal approach with Veritas bovine collagen matrix (Synovis, St. Paul, Minn., USA) were retrospectively evaluated. All wall repairs were reinforced with Veritas collagen matrix. The women were postmenopausal and used vaginal estrogen for at least 2 weeks preoperatively. Healing was assessed by prolapse recurrence and the presence of infection, granulation tissue and suture materials in the vagina postoperatively. Results: None of the 18 patients developed a postoperative vaginal infection, and none had vaginal erosion of the material. No patient had tissue disruption at the suture lines. The followup examinations were immediately after surgery and after 6, 12 and 18 months (median 15 months). There were no vessel or bladder injuries. One hematoma was noted but no other postoperative complication. One nonsymptomatic recurrent cystocele was described. Conclusion: The Veritas collagen matrix implant does not appear to impede healing in vaginal urogynecological surgery. These preliminary results suggest that bovine collagen implantation is a safe and effective treatment for anterior vaginal wall prolapse. Further studies with longer follow-ups are needed.","PeriodicalId":12827,"journal":{"name":"Gynakologisch-geburtshilfliche Rundschau","volume":"48 1","pages":"31-4"},"PeriodicalIF":0.0,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000111468","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41077100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Fetal programming]. (“胎儿规划)。

Gynakologisch-geburtshilfliche Rundschau Pub Date : 2008-01-01 Epub Date: 2008-12-03 DOI: 10.1159/000154803

U Lang, D Fink, R Kimmig

引用次数: 0